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Small molecules that inhibit common cancer-associated changes in metabolism have great potential as
widely applicable therapies. In this issue of Chemistry & Biology, Kung et al. report the characterization of
a small molecule activator of the enzyme pyruvate kinase M2, which reprograms cancer cell metabolism re-
sulting in dependence on the amino acid serine.Under aerobic conditions in adult tissues,
the majority of glucose is metabolized to
pyrvuate that then enters the tricarboxylic
acid cycle to generate large amounts of
ATP and CO2 through oxidative phos-
phorylation. However, under conditions
where oxygen is limiting, cells can use
the less efficient glycolysis pathway to
generate ATP and lactate. In the early
20th century, Otto Warburg observed
that cancer cells use much higher
amounts of glucose and predominantly
convert it to lactate through glycolysis
even in the presence of oxygen (Warburg,
1956). This phenomenon, termed aerobic
glycolysis, is a common feature of many
rapidly proliferating cells, including the
vast majority of cancers. Therefore, there
is much interest in identifying the proteins
responsible for these changes in metabo-
lism, as they would be potential thera-
peutic targets. One such protein that is
associated with the switch to aerobic
glycolysis is a specific isoform of pyruvate
kinase (PK). PK catalyzes the conversion
of phosphoenolpyruvate to pyruvate and
ATP. Four different isoforms of PK exist
in mammals (L, R, M1, and M2). The L
and R isoforms are expressed in the liver
and red blood cells, respectively, whereas
the M1 isoform is expressed in most
adult tissues. In contrast, PKM2 is found
during development and in rapidly prolif-
erating tissues (Mazurek, 2011). Previous
experiments have demonstrated that
PKM2 predominates in cancer cells
instead of other isoforms, including
PKM1, somuch so that it is a viable serum
biomarker of disease.
These two isoforms arise from an
alternative messenger RNA splicing event
that results in the exclusive inclusion
of exon 9 (PKM1) or exon 10 (PKM2).
Although this results in only a small
primary sequence difference (only 221084 Chemistry & Biology 19, September 21,amino acids in humans), it has profound
effects on protein tertiary and quaternary
structure. PKM1 exists as a constitutive
tetramer that is largely unregulated,
resulting in high enzymatic activity. In
contrast, PKM2 is regulated by allostery
and posttranslational modifications.
These regulators allow PKM2 to display
an enzymatic versatility not seen in
PKM1. Specifically, PKM2’s activity is
controlled by alternating between tetra-
meric (high-activity) and dimeric or
potentially monomeric (low-activity)
states (Landt et al., 2010). This enables
cancer cells to control the flowof nutrients
between metabolite generation and
mitochondrial ATP production. There are
both positive and negative regulators of
PKM2 activity. For example, fructose-
1,6-bisphosphate, an upstream metabo-
lite, binds in an allosteric pocket and
activates PKM2by stabilizing the tetramer
(Ashizawa et al., 1991). In contrast, direct
tyrosine phosphorylation (Presek et al.,
1988) and binding of phosphotyrosine
proteins in the same allosteric pocket
result in formation of PKM2 dimers during
proliferative signaling (Christofk et al.,
2008b). Additionally, oxidative stress
results in PKM2 dimer formation (Anasta-
siou et al., 2011). Specifically, cysteine
residue 358 can be oxidized and prevent
tetramer formation, and this modification
is required for PKM2 to promote survival
of cancer cells during oxidative stress
and tumorigenesis. Finally, the activity of
PKM2 can be irreversibly decreased
through autophagy-mediated degrada-
tion that is dependent upon acetylation
of PKM2 at lysine residue 305 (Lv
et al., 2011). Somewhat counterintuitively,
unlike other oncogenes the reduced
catalytic activity of the PKM2 dimer
appears to promote tumorigenesis by
allowing glycolytic intermediates to be2012 ª2012 Elsevier Ltd All rights reservedutilized for the biosynthesis of molecules
necessary for proliferation and survival.
In fact, replacing PKM2 with PKM1 re-
sulted in reduced tumorigenesis in vivo
(Christofk et al., 2008a).
Therefore, small molecules that acti-
vate PKM2 by locking the enzyme into
its high-activity tetrameric conformation
may produce similar effects. Several
such activators have been reported, but
the molecular consequences on cancer
metabolismwere unexplored. In this issue
of Chemistry & Biology, Kung et al. (2012)
report the development and careful char-
acterization of a new series of small-mole-
cule activators of PKM2. They demon-
strate that these molecules bind at the
tetramer interface of PKM2 and lock the
enzyme into an active state that is com-
pletely resistant to deactivating stimuli,
including interactions with phosphotyro-
sine-modified proteins. Importantly, this
activation is preserved in cancer cells,
enabling the authors to perform clever
cellular analysis of these molecules to
understand the consequences of artificial
PKM2 activation. Specifically, the authors
use a combination of protein expression
analysis, metabolomics, and isotopic
tracing to uncover an unexpected link
between glucose and amino acid metab-
olism. PKM2 activation in A549 lung
cancer cells resulted in an absolute
dependence upon the nonessential amino
acid serine for proliferation because of
increased flux of glycolytic intermediates
through PKM2, in effect ‘‘stealing’’ them
away from the serine biosynthetic path-
way. Because nutrient availability can
vary for tumors in vivo, drugs such as
these that limit the ability of cancer
metabolism to adapt cells to changing
environmental conditions have great
promise for future therapeutic develop-
ment. In fact, a recent publication from
Chemistry & Biology
Previewsthe same team of investigators demon-
strated that oral administration of another
PKM2 activator resulted in inhibition of
tumor growth in a xenograft model (Anas-
tasiou et al., 2012).
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